Although recent advances in the treatment of multiple myeloma have improved survival, it remains a chronic disease that requires a long-term treatment strategy. The key to achieving the best outcomes for patients is delivering the best “package” of treatment at a given stage. This means using optimal combinations that maximize benefit based on what patients have received previously and minimize treatment-related toxicity. Sequencing of regimens also plays an important role. As new agents and new classes of drugs continue to be approved for multiple myeloma, future strategies will use more individualized approaches to treatment.
|Original language||English (US)|
|Number of pages||4|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Dec 2020|
ASJC Scopus subject areas